Is Target a Dividend King?
Popular retail giant Target Corporation (NYSE:TGT) has been in a…
Sell
15
TWST Quote, Financials, Valuation and Earnings
Last price:
$42.75
Seasonality move
:
-12.14%
Day range:
$42.28 - $45.97
52-week range:
$27.41 - $60.90
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
8.08x
P/B ratio:
5.49x
Volume:
489.4K
Avg. volume:
750.5K
1-year change:
20.65%
Market cap:
$2.6B
Revenue:
$313M
EPS (TTM):
-$3.60
Analysts' Opinion
-
Consensus RatingTwist Bioscience has received a consensus rating of Buy. The company's average rating is a Buy based on 6 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $52.14, Twist Bioscience has an estimated upside of 19.64% from its current price of $43.58.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $35.00 representing 100% downside risk from its current price of $43.58.
Fair Value
-
According to the consensus of 8 analysts, Twist Bioscience has 19.64% upside to fair value with a price target of $52.14 per share.
TWST vs. S&P 500
-
Over the past 5 trading days, Twist Bioscience has underperformed the S&P 500 by -6.63% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Twist Bioscience does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Twist Bioscience has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Twist Bioscience reported revenues of $84.7M.
Earnings Growth
-
Twist Bioscience has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Twist Bioscience reported earnings per share of -$0.59.
Enterprise value:
2.3B
EV / Invested capital:
--
Price / LTM sales:
8.08x
EV / EBIT:
--
EV / Revenue:
7.41x
PEG ratio (5yr expected):
-3.49x
EV / Free cash flow:
-33.54x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$133.3M
Return On Assets:
-30.12%
Net Income Margin (TTM):
-66.69%
Return On Equity:
-38.12%
Return On Invested Capital:
-38.12%
Operating Margin:
-42.55%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $203.6M | $245.1M | $313M | $66.9M | $84.7M | |
| Gross Profit | $84.2M | $89.7M | $133.3M | $24.5M | $38.2M | |
| Operating Income | -$249M | -$206.9M | -$175.9M | -$46.6M | -$36M | |
| EBITDA | -$211.7M | -$174.2M | -$176.7M | -$38M | -$28.1M | |
| Diluted EPS | -$4.03 | -$3.60 | -$3.60 | -$0.81 | -$0.59 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $334.9M | $546.5M | $596.5M | $424.3M | $346.8M | |
| Total Assets | $398.9M | $702.1M | $961.4M | $776.4M | $614.3M | |
| Current Liabilities | $36M | $63.1M | $90.7M | $73.3M | $71M | |
| Total Liabilities | $62.6M | $121.3M | $172M | $153M | $141.6M | |
| Total Equity | $336.3M | $580.8M | $789.4M | $623.4M | $472.7M | |
| Total Debt | $4.7M | $1.6M | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$124.4M | -$142.5M | -$64.1M | -$20.7M | -$15.3M | |
| Cash From Investing | -$232.9M | $50.6M | -$3.1M | -$2.2M | -$1.3M | |
| Cash From Financing | $270.5M | $911K | $6.9M | $442K | $3.6M | |
| Free Cash Flow | -$226.2M | -$170.3M | -$69.2M | -$23.1M | -$17.3M | |
TWST
Sector
Market Cap
$2.6B
$46.7M
Price % of 52-Week High
71.56%
46.54%
Dividend Yield
0%
0%
Shareholder Yield
0.15%
-0.74%
1-Year Price Total Return
20.65%
-33.88%
Beta (5-Year)
1.846
0.752
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$45.69
200-day SMA
Sell
Level
$44.42
Bollinger Bands (100)
Sell
Level
0 - 0
Chaikin Money Flow
Sell
Level
--
20-day SMA
Sell
Level
$46.76
Relative Strength Index (RSI14)
Sell
Level
39.06
ADX Line
Neutral
Level
0
Williams %R
Neutral
Level
-75.4146
50-day SMA
Sell
Level
$45.99
MACD (12, 26)
Sell
Level
-0.58
25-day Aroon Oscillator
Sell
Level
-88
On Balance Volume
Neutral
Level
--
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (8.3686)
Sell
CA Score
(Annual)
Level (-0.3151)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (1.5974)
Buy
Piotroski F Score
(Annual)
Level (4)
Sell
Quality Ratio Score
Level (4)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well-plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to realize opportunities ahead rapidly. Geographically, it derives a majority of its revenue from the United States.
Stock Forecast FAQ
In the current month, TWST has received 6 Buy ratings 2 Hold ratings, and 0 Sell ratings. The TWST average analyst price target in the past 3 months is $52.14.
-
Where Will Twist Bioscience Stock Be In 1 Year?
According to analysts, the consensus estimate is that Twist Bioscience share price will rise to $52.14 per share over the next 12 months.
-
What Do Analysts Say About Twist Bioscience?
Analysts are divided on their view about Twist Bioscience share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Twist Bioscience is a Sell and believe this share price will drop from its current level to $35.00.
-
What Is Twist Bioscience's Price Target?
The price target for Twist Bioscience over the next 1-year time period is forecast to be $52.14 according to 8 Wall Street analysts, 6 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is TWST A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Twist Bioscience is a Buy. 6 of 8 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of TWST?
You can purchase shares of Twist Bioscience via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Twist Bioscience shares.
-
What Is The Twist Bioscience Share Price Today?
Twist Bioscience was last trading at $42.75 per share. This represents the most recent stock quote for Twist Bioscience. Yesterday, Twist Bioscience closed at $43.58 per share.
-
How To Buy Twist Bioscience Stock Online?
In order to purchase Twist Bioscience stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is COWZ ETF a Good Investment?
There’s a reason even Warren Buffett advocates his heirs to…
3 Stocks Buffett Is Betting On
Warren Buffett appeared to take a hard look at the…
Stock Ideas
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 38x
Sell
46
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 112x
Sell
40
Is MSFT Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
61
ITCI alert for Jan 14
Intra-Cellular Therapies [ITCI] is down 0.26% over the past day.
Sell
30
ESTA alert for Jan 14
Establishment Labs Holdings [ESTA] is down 1.51% over the past day.
Buy
72
DJT alert for Jan 15
Trump Media & Technology Group [DJT] is down 8.25% over the past day.
